What BrainCo says

BrainCo's founding partner, Nyx He, told Bloomberg that the Hangzhou company is developing a device that could suppress appetite through brain stimulation. The interview was given at Bloomberg Tech London and reported on or around 3 November 2026. What follows is what the company says. We have not verified any of it.

  • He describes the device as an electronic version of GLP-1 obesity medications. This is our paraphrase, translated from the Portuguese reprint of Bloomberg's report.
  • The company plans a launch within two to three years, first in China, with a possible expansion to the United States later.
  • Separate medical and consumer versions are under consideration. The company has not decided on either.
  • BrainCo may later move into approaches that need implanted brain electrodes, He said.

What is documented

  • BrainCo is based in Hangzhou. Its current products are brain-computer interface headsets used for autism, ADHD and insomnia support, and prosthetic hands, according to Bloomberg.
  • In January 2026 Bloomberg reported that BrainCo had filed confidentially for a Hong Kong initial public offering. The company declined to comment on timing. We did not read the filing itself.
  • Bloomberg describes the device as a potential non-drug alternative to GLP-1 weight-loss drugs such as Wegovy and Zepbound. That framing is Bloomberg's, not the company's.

What has not been published

In the sources we read, we found no clinical trial, no efficacy data and no weight-loss results. We found no safety data and no technical specification, such as where the stimulation would be applied or how strong it would be. We found no regulatory filing, approval or classification for this device in China, the United States or elsewhere. We found no announcement from BrainCo about the device itself, and the company's website is minimal.

Why the GLP-1 comparison matters

Calling a device an electronic version of GLP-1 medication invites comparison with drugs that have large trial programmes behind them. No such programme for this device has been published. The comparison sets an expectation about results that the company has not supported.

Analysis: a product marketed to reduce appetite makes a medical claim on its face. Whether regulators would treat it as a medical device depends on rules the company has not addressed in public. We do not state a classification here.

Questions the company has not answered

  • What does the stimulation do, where is it applied, and at what strength?
  • What evidence shows that it reduces appetite or body weight, and in whom was it tested?
  • Who would regulate it in China and in the United States, and under which classification?
  • What data would a user's device collect, and who could access it? The company has not said. This question is our analysis, not a reported fact about BrainCo.

What we are not claiming

We are not saying that the device exists as a product, that it works, or that it is safe. The company describes a plan. Treat the claims in this article as BrainCo's until the company publishes data or a regulator acts.

Sources: Bloomberg Línea, reprint of a Bloomberg report on BrainCo, 3 November 2026 (Portuguese; quotations are our translation from the reprint). BrainCo homepage (no announcement of the device found).